newsfilter
← Earnings
Earnings Releases·

Teva Pharmaceutical Industries Ltd. — Third Quarter 2026 Earnings Summary

Teva Pharmaceutical Industries reported third-quarter 2026 revenues of $4.4 billion, a 2% decrease year-over-year driven by lower generic sales, while key innovative brands collectively grew 33% to approximately $1.1 billion. The company raised its 2026 revenue outlook for AUSTEDO, AJOVY, and UZEDY, citing strong performance and the recent FDA approval of the schizophrenia treatment WELTRUZA. Non-GAAP gross profit margin expanded to 58.7%, the highest quarterly level in the last decade, and the company achieved investment-grade credit ratings following a $4.9 billion debt refinancing.

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic